NORWOOD,
Mass., Sept. 12, 2022 /PRNewswire/ -- Corbus
Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the
"Company"), today announced that Yuval
Cohen, Ph.D., Chief Executive Officer of Corbus, will
present virtually at the H.C. Wainwright 24th Annual Global
Investment Conference. The hybrid conference will take
place September 12-14,
2022.
A livestream of the virtual presentation is available on-demand
beginning today, Monday, September 12,
2022 at 7:00 AM ET for those
who are registered to attend the conference and will be accessible
for 30 days on the H.C. Wainwright conference platform. For more
information, please visit the conference website.
About Corbus
Corbus is an immunology company committed to helping people
defeat serious illness by bringing innovative scientific approaches
to well understood biological pathways. Corbus' current
pipeline includes anti-integrin monoclonal antibodies that block
activation of TGFβ and small molecules that activate or inhibit the
endocannabinoid system. Corbus is headquartered in Norwood, Massachusetts. For more information
on Corbus, visit corbuspharma.com. Connect with us on Twitter,
LinkedIn and Facebook.
INVESTOR CONTACT:
Sean
Moran
smoran@corbuspharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/corbus-pharmaceuticals-to-present-virtually-at-the-hc-wainwright-24th-annual-global-investment-conference-301621611.html
SOURCE Corbus Pharmaceuticals